Waldencast plc
WALDU
NASDAQ Capital Market9.07
USD
+0.24
- -
Waldencast plc
WALDU
(NASDAQ Capital Market)
Recent
price
9.07
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Waldencast plc (NASDAQ: WALD, WALDU) operates as a global multi-brand beauty and wellness platform focused on building, acquiring, accelerating, and scaling high-growth, purpose-driven brands in skincare, makeup, and related categories. The company offers a portfolio of core brands including Obagi Medical, which provides medical-grade skincare products such as clinically-backed solutions for anti-aging, hyperpigmentation, acne, and recently launched hyaluronic acid injectables like Obagi saypha MagIQ and Nu-Cil BioStim Scalp Serum; Milk Makeup, featuring clean, cruelty-free, vegan cosmetics encompassing foundations, concealers, primers, blushes, bronzers, liners, eyeshadows, lip colors, and setting sprays; and additional offerings through brands like K18 for biotech-based hair repair treatments and Nudestix for minimalist multi-functional makeup sticks. Products are distributed to physicians, dermatologists, plastic surgeons, medical spas, retailers, distributors, and consumers via e-commerce platforms, direct-to-consumer channels, and third-party logistics, with strategic emphasis on prestige beauty segments including skincare, haircare, and makeup. Waldencast serves target markets of conscious consumers, professionals in aesthetics, and trend-driven demographics like Gen Z and millennials, operating geographically across North America, Southeast Asia, and expanding into international regions such as APAC. Founded in 2021 through a SPAC merger and headquartered in White Plains, New York, the company initially went public in 2021 and completed key acquisitions of Obagi Skincare and Milk Makeup in 2022 to establish its platform model. Recent major developments include the 2025 acquisition of Novaestiq Corp., which doubles Obagi Medical's addressable market by adding injectable dermal fillers like Saypha products with cash, royalties, and contingent share issuances tied to $100 million and $200 million net sales milestones; FDA approval and launch of Obagi saypha MagIQ injectable hyaluronic acid gel; the sale of the Obagi Japan trademark for $82.5 million to strengthen its balance sheet; refinancing of credit facilities; double-digit growth in core strategic channels during H1 2025 with net revenues reaching $66.8 million in Q2 2025 and an Adjusted EBITDA margin of 5.0%; launch of Nu-Cil BioStim Scalp Serum and new clinical data presentations; expanded international investments including Ulta Beauty partnerships, Amazon Premium Beauty presence, and Southeast Asia relaunch strategies; and an ongoing strategic review of alternatives to maximize shareholder value following board-approved long-range business plan updates.
Waldencast Acquisition Corp. Announces the Separate Trading of Its Class A Ordinary Shares and Redeemable Warrants Commencing May 10, 2021